Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood vessel on a chip could transform bleeding risk tests

NCT ID NCT03773159

Diagnosis Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new device that mimics a blood vessel to evaluate how well a person's blood clots under realistic flow conditions. Researchers will compare results from healthy donors, patients with von Willebrand disease, and those on antiplatelet drugs. The goal is to see if this test can more accurately identify bleeding risk than current methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood sampling
What this could lead to
If successful, this could lead to a more accurate blood test to predict bleeding risk in people with clotting disorders or those taking blood thinners.
What could go wrong
This is an early-stage study focused on test accuracy, not a treatment. The device may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2019

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with von Willebrand disease or major constitutional thrombopathy or patient on antiplatelet drugs

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * person who has given oral consent * adult * blood donor at EFS Bourgogne Franche-Comté * or patient with von Willebrand disease or major constitutional thrombopathy followed by the Resource and Competence Centre (CRC) - Constitutional Hemorrhagic Diseases of Dijon or Besançon * or patient on antiplatelet drugs consulting for thrombosis at the Dijon Bourgogne or Besançon Hospital Exclusion Criteria: * a person who is not affiliated to or not a beneficiary of national health insurance * person subject to court-ordered protection (curatorship, guardianship) * pregnant, parturient or breastfeeding woman * a person who is unable to consent * person on anti-inflammatory treatment and serotonin reuptake inhibitor antidepressants (platelet function disorders)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major constitutional thrombopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood platelet disease hereditary von Willebrand disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major constitutional thrombopathy Patient on antiplatelet drugs Von Willebrand diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Dijon Bourgogne

    RECRUITING

    Dijon, France

  • CHU de Besançon

    RECRUITING

    Besançon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.